insights - IMS Health

EXPERTISE | IMS
Claude Le Pen, PHD
• Dr. Claude Le Pen is a member of the strategic committee of IMS Health and Professor of Health
Economics at Paris-Dauphine University, providing expert economic advisory services to the
consulting practice.
• A renowned economist, leading academic, and respected public commentator, Claude has served
as an appointed senior member of several state commissions in the French Ministry of Health and
is an expert for a number of parliamentary bodies, bringing a unique perspective and unparalleled
insights into the economic evaluation of pharmaceutical technologies at the highest level.
• Claude studied Business Administration in HEC Business School in Paris and holds a PhD in
Economics from Panthéon-Sorbonne University.
Adam Lloyd, MPHIL, BA
• Adam Lloyd is Senior Principal HEOR at IMS Health, with a particular focus on economic modeling
and the global application of economic tools to support the needs of local markets.
• A former founder and Director of Fourth Hurdle, and previously Senior Manager of Global Health
Outcomes at GlaxoWellcome, Adam has extensive experience leading economic evaluations of prelaunched
and marketed products, developing submissions to NICE and the SMC, decision-analytic
and Markov modeling, and in the use of health economics in reimbursement and marketing in
continental Europe.
• Adam holds an MPhil in Economics, and a BA (Hons) in Philosophy, Politics and Economics from the
University of Oxford.
Charles Makin, MS, MBA, MM, BS
• Charles Makin is Principal HEOR at IMS Health, focusing on naturalistic trials, adherence
interventions, chart abstractions, patient-reported outcomes and other studies involving
primary data collection.
• During a career that includes senior roles at the UnitedHealth Group and Wellpoint, Charles has
led numerous studies involving database analyses, economic modeling, multi-country patient
registries, systematic literature reviews and survey-based research.
• Charles holds a BS in Pharmacy from the University of Pune, India, an MS in Pharmacy
Administration from Purdue University, Indiana, U.S. and an MBA in Marketing Management and
a Master’s in Management, both from Goldey Beacom College, Delaware, U.S.
Frédérique Maurel, MS, MPH
• Frédérique Maurel is Principal HEOR at IMS Health, with a particular focus on observational research
and health economics studies.
• A skilled consultant and project manager, Frédérique has extensive experience in the economic
evaluation of medical technologies gained in roles at ANDEM, Medicoeconomie, and AREMIS
Consultants.
• Frédérique holds a Masters degree in Economics – equivalent to an MS – and completed a postgraduate
degree equivalent to an MPH with a specialization in Health Economics at the University
of Paris-Dauphine (Paris IX) as well as a degree in Industrial Strategies at the Pantheon-Sorbonne
University (Paris I).
Joan McCormick, MBA
• Joan McCormick is Principal at IMS Brogan, leading a team providing strategic advice to
companies with new products coming to market and ongoing consultation on the rules for
existing drugs post launch.
• Formerly Head of Price Regulation Consulting at Brogan Inc, Joan has supported many major
pharmaceutical companies with the preparation of pricing submissions to the Patented
Medicine Prices Review Board (PMPRB), gaining extensive insights into the operation of the
Canadian pharmaceutical market.
• Joan holds a Bachelor’s degree in Life Sciences from Queen’s University in Kingston, Canada,
and an MBA from the University of Ottawa, Canada.
ACCESSPOINT AccessPoint ACCESSPOINT - • Issue VOLUME 3 2 ISSUE 4 PAGE Page 61
61